bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE - Free Report) in a research note published on Friday. The firm issued a sell rating on the biotechnology company's stock.

A number of other equities analysts have also recently weighed in on BLUE. Cantor Fitzgerald restated a "neutral" rating on shares of bluebird bio in a report on Monday, September 16th. Bank of America lowered shares of bluebird bio from a "buy" rating to a "neutral" rating and lowered their price target for the company from $60.00 to $10.00 in a report on Friday, November 15th. JPMorgan Chase & Co. lowered shares of bluebird bio from a "neutral" rating to an "underweight" rating in a report on Friday, November 15th. Royal Bank of Canada restated a "sector perform" rating and set a $80.00 target price on shares of bluebird bio in a research note on Friday, November 15th. Finally, Wells Fargo & Company cut their price target on bluebird bio from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Wednesday, September 25th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $49.14.

bluebird bio Stock Down 7.9 %

Shares of NASDAQ:BLUE traded down $0.73 during midday trading on Friday, hitting $8.50. 899,239 shares of the company's stock traded hands, compared to its average volume of 398,183. The firm's fifty day moving average price is $8.57 and its two-hundred day moving average price is $13.75. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio has a twelve month low of $5.80 and a twelve month high of $38.40. The company has a market cap of $82.64 million, a PE ratio of -4.55 and a beta of 0.72.

bluebird bio (NASDAQ:BLUE - Get Free Report) last issued its quarterly earnings data on Friday, September 27th. The biotechnology company reported ($8.40) EPS for the quarter, missing analysts' consensus estimates of ($8.00) by ($0.40). bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The company had revenue of $16.10 million for the quarter, compared to analyst estimates of $16.09 million. On average, equities research analysts anticipate that bluebird bio will post -1.35 EPS for the current fiscal year.

Institutional Trading of bluebird bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its stake in bluebird bio by 315.3% in the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock valued at $1,223,000 after buying an additional 1,013,144 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company's stock worth $193,000 after acquiring an additional 355,562 shares during the period. FMR LLC lifted its position in bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company's stock valued at $1,289,000 after purchasing an additional 186,903 shares during the last quarter. Barclays PLC boosted its stake in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after purchasing an additional 184,605 shares during the period. Finally, Geode Capital Management LLC boosted its stake in bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company's stock valued at $2,433,000 after purchasing an additional 166,771 shares during the period. 87.43% of the stock is currently owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.